NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Inomagen Therapeutics

Inomagen Therapeutics

Private
Chicago, IllinoisHealthcare & Life Scienceshttps://inomagen.com/

Last Round

Seed

Aug 1, 2024

Total Funding Raised

$4.07M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Inomagen Therapeutics is a biotechnology company developing a non-viral gene therapy designed to treat the underlying mechanisms of atrial fibrillation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Devices, Precision Medicine

Business Model

B2B2C

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

gene therapyatrial fibrillationAFibnon-viral gene therapycardiac gene therapyreversible electroporationgene silencingtranscatheter gene deliverydisease modifying therapyNOX2 gene silencingnaked DNA deliverycatheter delivery systempreclinical biotecharrhythmia treatmentshRNA therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inomagen Therapeutics Comparables

Compare Inomagen Therapeutics with similar companies based on industry and business-model similarity.

Inomagen Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rhythm Biotherapeutics
75%
Renova Therapeutics
70%
Medera
66%

Inomagen Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 1, 2024
Convertible DebtJan 1, 2023
GrantMar 11, 2022

Key People

Founding team and executive leadership

Linda S.

Interim CFO

Executive Team

Inomagen Therapeutics Investors

Notable investors and investment history

Inomagen Therapeutics investors
InvestorRounds
NIH RADxGrant
National Heart, Lung, and Blood InstituteGrant
Portal InnovationsConvertible Debt
Chicago ArchAngelsConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors grew 938% MoM, from 128 to 1.3K.

  • Aug 1, 2024

    Raised $5M in seed funding.

Inomagen Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Inomagen Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Inomagen Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersChicago, Illinois
Employee Range6
Year Founded2014
Last FundingAug 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.